Document is current
Any future updates will be listed below
-
Authors
Huang, Xin https://orcid.org/0000-0001-6778-8849
Park, Kyoung-mi
Gontarz, Paul
Zhang, Bo https://orcid.org/0000-0003-2962-5314
Pan, Joshua
McKenzie, Zachary
Fischer, Laura A.
Dong, Chen https://orcid.org/0000-0002-5405-5715
Dietmann, Sabine
Xing, Xiaoyun https://orcid.org/0000-0002-1045-1775
Shliaha, Pavel V.
Yang, Jihong https://orcid.org/0000-0002-2753-0939
Li, Dan https://orcid.org/0000-0002-6332-1093
Ding, Junjun https://orcid.org/0000-0002-9936-882X
Lungjangwa, Tenzin
Mitalipova, Maya
Khan, Shafqat A.
Imsoonthornruksa, Sumeth
Jensen, Nick https://orcid.org/0000-0002-1177-3418
Wang, Ting https://orcid.org/0000-0002-6800-242X
Kadoch, Cigall https://orcid.org/0000-0002-4058-5985
Jaenisch, Rudolf https://orcid.org/0000-0002-2540-7099
Wang, Jianlong https://orcid.org/0000-0002-1317-6457
Theunissen, Thorold W. https://orcid.org/0000-0001-6943-7858
- License Information
-
More Information
Article History
Received: 19 April 2021
Accepted: 12 July 2021
First Online: 26 August 2021
Competing interests
: R.J. is a cofounder of Fate Therapeutics, Fulcrum Therapeutics, and Omega Therapeutics, and an advisor to Dewpoint Therapeutics. C.K. is the Scientific Founder, fiduciary Board of Directors member, Scientific Advisory Board member, shareholder, and consultant for Foghorn Therapeutics. The remaining authors declare no competing interests.
